Goldman Sachs’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-58,900
| Closed | -$5.01M | – | 5882 |
|
|
2020
Q3 | $5.01M | Buy |
58,900
+14,400
| +32% | +$728K | ﹤0.01% | 2902 |
|
|
2020
Q2 | $1.58M | Buy |
44,500
+22,400
| +101% | +$655K | ﹤0.01% | 3622 |
|
|
2020
Q1 | $298K | Buy |
+22,100
| New | +$372K | ﹤0.01% | 4506 |
|
|
2018
Q2 | – | Sell |
-58,400
| Closed | -$853K | – | 6167 |
|
|
2018
Q1 | $853K | Hold |
58,400
| – | – | ﹤0.01% | 4149 |
|
|
2017
Q4 | $944K | Buy |
+58,400
| New | +$689K | ﹤0.01% | 4366 |
|
|
2016
Q3 | – | Sell |
-3,400
| Closed | -$8K | – | 7270 |
|
|
2016
Q2 | $8K | Buy |
+3,400
| New | +$11.4K | ﹤0.01% | 6890 |
|
|
2016
Q1 | – | Sell |
-90,300
| Closed | -$277K | – | 7425 |
|
|
2015
Q4 | $277K | Sell |
90,300
-58,800
| -39% | -$164K | ﹤0.01% | 5418 |
|
|
2015
Q3 | $256K | Sell |
149,100
-7,500
| -5% | -$19.1K | ﹤0.01% | 5754 |
|
|
2015
Q2 | $636K | Buy |
+156,600
| New | +$640K | ﹤0.01% | 4941 |
|
|
2014
Q1 | – | Sell |
-390,800
| Closed | -$1.8M | – | 6994 |
|
|
2013
Q4 | $1.8M | Buy |
+390,800
| New | +$1.74M | ﹤0.01% | 4189 |
|
Goldman Sachs's IMMU Position: Q4 2020 in Review
Goldman Sachs sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 4,916,448 shares — an estimated $418M sold.
Goldman Sachs first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $418M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Goldman Sachs reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 4,916,448 Immunomedics Inc shares in Q4 2020, an estimated $418M.
- Goldman Sachs first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
- Goldman Sachs's Immunomedics Inc position peaked at $418M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.